ARWR – Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.ARWR
$16.03Name : Arrowhead Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,213,052,416.00
EPSttm : -1.24
Arrowhead Pharmaceuticals, Inc.
$16.03
0.34%$0.055Float Short %
11.01
Margin Of Safety %
-31
Put/Call OI Ratio
0.6
EPS Next Q Diff
-3.17
EPS Last/This Y
4.97
EPS This/Next Y
-3.27
Price
16.08
Target Price
41.77
Analyst Recom
1.62
Performance Q
16.52
Relative Volume
1.09
Beta
0.95
Ticker: ARWR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | ARWR | 16.4 | 1.39 | 0.18 | 36226 |
| 2025-06-03 | ARWR | 16.61 | 1.37 | 0.08 | 36469 |
| 2025-06-04 | ARWR | 16.74 | 1.36 | 0.13 | 36587 |
| 2025-06-05 | ARWR | 16.46 | 1.36 | 0.05 | 36757 |
| 2025-06-06 | ARWR | 16.8 | 1.36 | 0.14 | 36773 |
| 2025-06-09 | ARWR | 16.57 | 1.35 | 0.00 | 36851 |
| 2025-06-10 | ARWR | 16.98 | 1.35 | 0.04 | 36899 |
| 2025-06-11 | ARWR | 16.75 | 1.34 | 0.94 | 36993 |
| 2025-06-12 | ARWR | 16.23 | 1.34 | 5.33 | 37267 |
| 2025-06-13 | ARWR | 15.75 | 1.31 | 0.15 | 36751 |
| 2025-06-16 | ARWR | 15.7 | 1.32 | 0.96 | 36677 |
| 2025-06-17 | ARWR | 15.49 | 1.32 | 0.14 | 36836 |
| 2025-06-18 | ARWR | 15.62 | 1.31 | 0.44 | 36684 |
| 2025-06-20 | ARWR | 15.32 | 1.30 | 0.76 | 36485 |
| 2025-06-23 | ARWR | 15.51 | 0.60 | 0.65 | 14283 |
| 2025-06-24 | ARWR | 15.94 | 0.60 | 0.00 | 14374 |
| 2025-06-25 | ARWR | 15.65 | 0.60 | 1.26 | 14473 |
| 2025-06-26 | ARWR | 16.07 | 0.60 | 0.23 | 14599 |
| 2025-06-27 | ARWR | 16.08 | 0.60 | 0.48 | 14621 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | ARWR | 16.42 | 20.2 | 451.0 | -0.18 |
| 2025-06-03 | ARWR | 16.61 | 20.2 | -303.1 | -0.18 |
| 2025-06-04 | ARWR | 16.74 | 20.2 | -300.1 | -0.18 |
| 2025-06-05 | ARWR | 16.46 | 20.2 | -286.6 | -0.18 |
| 2025-06-06 | ARWR | 16.79 | 20.2 | -307.5 | -0.18 |
| 2025-06-09 | ARWR | 16.57 | 20.2 | -288.0 | -0.18 |
| 2025-06-10 | ARWR | 16.97 | 20.2 | -309.5 | -0.18 |
| 2025-06-11 | ARWR | 16.74 | 20.2 | -288.5 | -0.18 |
| 2025-06-12 | ARWR | 16.22 | 20.2 | -278.6 | -0.18 |
| 2025-06-13 | ARWR | 15.74 | 20.2 | -279.2 | -0.18 |
| 2025-06-16 | ARWR | 15.69 | 20.2 | -294.1 | -0.18 |
| 2025-06-17 | ARWR | 15.50 | 20.2 | -288.7 | -0.18 |
| 2025-06-18 | ARWR | 15.62 | 20.2 | -300.4 | -0.18 |
| 2025-06-20 | ARWR | 15.32 | 20.2 | -285.0 | -0.18 |
| 2025-06-23 | ARWR | 15.53 | 20.2 | -304.3 | -0.18 |
| 2025-06-24 | ARWR | 15.94 | 20.2 | -311.8 | -0.18 |
| 2025-06-25 | ARWR | 15.65 | 20.2 | -285.0 | -0.18 |
| 2025-06-26 | ARWR | 16.05 | - | -310.6 | 0.00 |
| 2025-06-27 | ARWR | 16.08 | - | -296.2 | -0.18 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | ARWR | -2.90 | 5.24 | 11.50 |
| 2025-06-03 | ARWR | -2.90 | 5.24 | 11.50 |
| 2025-06-04 | ARWR | -2.90 | 5.24 | 11.50 |
| 2025-06-05 | ARWR | -2.90 | 5.24 | 11.50 |
| 2025-06-06 | ARWR | -2.90 | 5.24 | 11.50 |
| 2025-06-09 | ARWR | -2.90 | 5.27 | 11.50 |
| 2025-06-10 | ARWR | -2.90 | 5.27 | 11.50 |
| 2025-06-11 | ARWR | -2.90 | 5.27 | 11.55 |
| 2025-06-12 | ARWR | -2.90 | 5.27 | 11.55 |
| 2025-06-13 | ARWR | -2.90 | 5.27 | 11.55 |
| 2025-06-16 | ARWR | -2.90 | 5.22 | 11.55 |
| 2025-06-18 | ARWR | -2.90 | 5.22 | 11.55 |
| 2025-06-20 | ARWR | -2.81 | 5.22 | 11.55 |
| 2025-06-23 | ARWR | -2.70 | 5.25 | 11.55 |
| 2025-06-24 | ARWR | -2.65 | 5.25 | 11.55 |
| 2025-06-25 | ARWR | -2.65 | 5.25 | 11.55 |
| 2025-06-26 | ARWR | -2.65 | 5.25 | 11.01 |
| 2025-06-27 | ARWR | -2.65 | 5.25 | 11.01 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.75
Avg. EPS Est. Current Quarter
-1.1
Avg. EPS Est. Next Quarter
-0.42
Insider Transactions
-2.65
Institutional Transactions
5.25
Beta
0.95
Average Sales Estimate Current Quarter
29
Average Sales Estimate Next Quarter
115
Fair Value
11.02
Quality Score
35
Growth Score
44
Sentiment Score
43
Actual DrawDown %
82.8
Max Drawdown 5-Year %
-89
Target Price
41.77
P/E
Forward P/E
PEG
P/S
4.07
P/B
3.25
P/Free Cash Flow
482.75
EPS
-1.38
Average EPS Est. Cur. Y
-0.18
EPS Next Y. (Est.)
-3.45
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-26.41
Relative Volume
1.09
Return on Equity vs Sector %
-45
Return on Equity vs Industry %
-27.1
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
-296.2
Arrowhead Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 609
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
stock quote shares ARWR – Arrowhead Pharmaceuticals, Inc. Stock Price stock today
news today ARWR – Arrowhead Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ARWR – Arrowhead Pharmaceuticals, Inc. yahoo finance google finance
stock history ARWR – Arrowhead Pharmaceuticals, Inc. invest stock market
stock prices ARWR premarket after hours
ticker ARWR fair value insiders trading